Scholarlink

<p>Multiple sclerosis (MS) is characterized by invasion of the brain by effector memory T (T<sub>EM</sub>) lymphocytes that have been activated by repeated auto-antigen stimulation. Existing therapies target these and other autoreactive lymphocytes but their side effects include general immunosuppression and toxicity. Because the Kv1.3 potassium channel is highly expressed by chronically activated autoreactive T<sub>EM</sub>s, we investigated whether specific targeting of mitochondrial Kv1.3 using the pharmacological inhibitor PAPTP could selectively kill these T<sub>EM</sub>s in patients and mice with MS. 1 µM PAPTP targeted and reduced the number of autoreactive T<sub>EM</sub>s in blood samples from relapsing-remitting MS (RRMS) patients, leaving other T cell populations unaffected. Remarkably, pre-treatment of the entire T cell population with PAPTP during adoptive transfer of experimental autoimmune encephalomyelitis (EAE) killed T<sub>EM</sub>s and completely prevented disease onset in this mouse model. Moreover, PAPTP selectively eliminated activated T<sub>EM</sub>s and halted EAE progression when administered following disease onset. Our findings reveal the potential of PAPTP as an effective treatment for MS without adverse side effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Selective inhibition of mitochondrial Kv1.3 prevents and alleviates multiple sclerosis in vivo

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Beatrice Angi,
  • Tatiana Varanita,
  • Marco Puthenparampil,
  • Valentina Scattolini,
  • Michael Donadon,
  • Mitra Tavakoli,
  • Marta Favero,
  • Maguie El Boustani,
  • Matthias Soddemann,
  • Lucia Biasutto,
  • Diletta Arcidiacono,
  • Alberto Ongaro,
  • Andrea Mattarei,
  • Livio Trentin,
  • Gregory Wilson,
  • Erich Gulbins,
  • Paolo Gallo,
  • Ildiko Szabo

摘要

Multiple sclerosis (MS) is characterized by invasion of the brain by effector memory T (TEM) lymphocytes that have been activated by repeated auto-antigen stimulation. Existing therapies target these and other autoreactive lymphocytes but their side effects include general immunosuppression and toxicity. Because the Kv1.3 potassium channel is highly expressed by chronically activated autoreactive TEMs, we investigated whether specific targeting of mitochondrial Kv1.3 using the pharmacological inhibitor PAPTP could selectively kill these TEMs in patients and mice with MS. 1 µM PAPTP targeted and reduced the number of autoreactive TEMs in blood samples from relapsing-remitting MS (RRMS) patients, leaving other T cell populations unaffected. Remarkably, pre-treatment of the entire T cell population with PAPTP during adoptive transfer of experimental autoimmune encephalomyelitis (EAE) killed TEMs and completely prevented disease onset in this mouse model. Moreover, PAPTP selectively eliminated activated TEMs and halted EAE progression when administered following disease onset. Our findings reveal the potential of PAPTP as an effective treatment for MS without adverse side effects.